HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 52.7%

Neg 0% Neu 52.7% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.